Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PFSW
1801
DELISTED
PFSweb, Inc.
PFSW
| $4.32M | 0.01% |
523,339
-57,910
| -10% | -$414K |
|
1802
Marchex
MCHX
$82M
| $4.32M | 0.01% |
1,449,901
+182,659
| +14% | +$516K |
|
1803
Hawkins
HWKN
$2.74B
| $4.32M | 0.01% |
186,400
-36,302
| -16% | -$876K |
|
|
WLB
1804
DELISTED
Westmoreland Coal Company
WLB
| $4.31M | 0.01% |
885,500
+358,000
| +68% | +$3.13M |
|
1805
Smith & Nephew
SNN
$12.5B
| $4.31M | 0.01% |
123,700
-610,300
| -83% | -$20.7M |
|
|
SVC
1806
Service Properties Trust
SVC
$1.05B
| $4.31M | 0.01% |
29,580
-15,568
| -34% | -$2.38M |
|
|
SHLM
1807
DELISTED
Schulman (A.) Inc
SHLM
| $4.29M | 0.01% |
+133,948
| New | +$3.98M |
|
1808
Piper Sandler
PIPR
$5.41B
| $4.27M | 0.01% |
285,200
-164,800
| -37% | -$2.49M |
|
|
GIFI
1809
DELISTED
Gulf Island Fabrication
GIFI
| $4.27M | 0.01% |
368,329
+80,300
| +28% | +$808K |
|
1810
Clear Channel Outdoor Holdings
CCO
$1.19B
| $4.27M | 0.01% |
880,900
-56,000
| -6% | -$263K |
|
|
ISEE
1811
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.27M | 0.01% |
1,667,100
-191,200
| -10% | -$521K |
|
|
IPAS
1812
DELISTED
Ipass Inc Common Stock
IPAS
| $4.27M | 0.01% |
323,310
+7,930
| +3% | +$104K |
|
1813
Citizens & Northern Corp
CZNC
$466M
| $4.25M | 0.01% |
182,700
+7,591
| +4% | +$175K |
|
|
NXGN
1814
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
| $4.25M | 0.01% |
246,976
+73,819
| +43% | +$1.12M |
|
|
CHCT
1815
Community Healthcare Trust
CHCT
$432M
| $4.24M | 0.01% |
165,597
+25,597
| +18% | +$643K |
|
|
RAVN
1816
DELISTED
Raven Industries Inc
RAVN
| $4.23M | 0.01% |
127,000
-27,600
| -18% | -$890K |
|
|
SPNE
1817
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $4.21M | 0.01% |
365,500
+164,000
| +81% | +$1.54M |
|
1818
Imperial Oil
IMO
$64.5B
| $4.2M | 0.01% |
143,895
-214,695
| -60% | -$6.28M |
|
1819
John Wiley & Sons Class A
WLY
$2.61B
| $4.2M | 0.01% |
+79,600
| New | +$4.16M |
|
1820
OneMain Financial
OMF
$7.56B
| $4.2M | 0.01% |
+170,700
| New | +$4.01M |
|
|
SMMF
1821
DELISTED
Summit Financial Group, Inc.
SMMF
| $4.2M | 0.01% |
190,735
+3,400
| +2% | +$74.5K |
|
1822
Ionis Pharmaceuticals
IONS
$9.51B
| $4.19M | 0.01% |
82,414
-230,800
| -74% | -$10.7M |
|
1823
E.W. Scripps
SSP
$320M
| $4.18M | 0.01% |
+235,003
| New | +$4.59M |
|
1824
Old National Bancorp
ONB
$10.4B
| $4.18M | 0.01% |
242,324
+160,848
| +197% | +$2.69M |
|
1825
Codexis
CDXS
$171M
| $4.18M | 0.01% |
766,700
-27,900
| -4% | -$128K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.